Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16096341 | 0.85 | RBP4 (0.39) | FKBP1ADPP8DPP7RBP4MEN1 | |
| SCHEMBL21987460 | 0.79 | FKBP1A (0.36) | FKBP1ARBP4MEN1KMT2A | |
| SCHEMBL9199384 | 0.76 | NR1D1 (0.38) | FKBP1ARBP4RAB9A | |
| Trifluoroacetic Acid SCHEMBL14761998 | 0.76 | DPP8 (0.35) | FKBP1ADPP8DPP7 | |
| SCHEMBL17042173 | 0.75 | GLS (0.48) | EPHX1 | |
| SCHEMBL24930132 | 0.74 | FKBP1A (0.34) | FKBP1ARBP4CNR2 | |
| SCHEMBL18667410 | 0.73 | EPHX2 (0.43) | EPHX1DPP8DPP7EPHX2PDK2 | |
| SCHEMBL26760225 | 0.73 | EPHX2 (0.43) | EPHX1DPP8DPP7EPHX2PDK2 | |
| SCHEMBL4100243 | 0.73 | EPHX2 (0.43) | EPHX1DPP8DPP7EPHX2PDK2 | |
| SCHEMBL25587594 | 0.70 | RBP4 (0.40) | RBP4MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | FKBP1A 996/4885EPHX1 2138/4885DPP8 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.